Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5853-5859

  Samimi, Goli ^a   Varki, Nissi M ^a   Wilczynski, Sharon ^b   Safaei, Roohangiz ^a   Alberts, David S ^c   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; COPPER; CYCLOPHOSPHAMIDE; DOXORUBICIN; MENKES PROTEIN; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ION TRANSPORT; KIDNEY; LUNG CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; TESTIS;

ADENOSINE TRIPHOSPHATASES; ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CATION TRANSPORT PROTEINS; CISPLATIN; COPPER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE;

EID: 0347447284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990.
2. Perez, R. P., Hamilton, T. C., Ozols, R. F., and Young, R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Phila.), 71: 1571-1580, 1993.
3. Fink, D., Aebi, S., and Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4: 1-5, 1998.
4. Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., and Hamilton, T. C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res., 57: 850-856, 1997.
5. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 67: 1171-1176, 1993.
6. Waud, W. R. Differential uptake of diamminedichloroplatinum(II) in sensitive and resistant murine L1210 leukemia cell lines. Cancer Res., 47: 6549-6555, 1987.
7. Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T., and Frei, E., III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer, 47: 252-260, 1991.
8. Metcalfe, S. A., Cain, K.; and Hill, B. T. Possible mechanisms for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett., 31: 163-169, 1986.
9. Oldenburg, J., Begg, A. C., van Vugt, M. J. H., Ruevekamp, M., Schornagel, J. H., Pinedo, H. M., and Los, G. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res., 54: 487-493, 1994.
10. Wallner, K. E., DeGregorio, M. W., and Li, G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res., 46: 6242-6245, 1986.
11. Twentyman, P. R., Wright, K. A., Mistry, P., Kelland, L. R., and Murrer, B. A. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res., 52: 5674-5680, 1992.
12. Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J., and Harrap, K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res., 52: 1710-1716, 1992.
13. Mann, S. C., Andrews, P. A., and Howell, S. B. Short-term cisdiamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 25: 236-240, 1990.
14. Chau, Q., and Stewart, D. J. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant. Cancer Chemother. Pharmacol., 44: 193-202, 1999.
15. Andrews, P. A., and Albright, K. D. Role of membrane ion transport in cisplatin accumulation. In: S. B. Howell (ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 151-159. New York: Plenum Press, 1991.
16. Andrews, P. A., Mann, S. C., Huynh, H. H., and Albright, K. D. Role of the Na+, K+-ATPase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res., 51: 3677-3681, 1991.
17. Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z-S., Terada, K., Furukawa, T., Yang, X-L., Gao, H., Miura, N., Sugiyama, T., and Akiyama, S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 60: 1312-1316, 2000.
18. Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., and Takebayashi, Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin-based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP, LRP and BCRP. Int. J. Cancer, 101: 488-495, 2002.
19. Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M., Kuo, Y-M., Rochdi, M., and Howell, S. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res., 62: 6559-6565, 2002.
20. Safaei, R., Katano, K., Samimi, G., Naerdemann, W., and Howell, S. Cisplatin resistance is mediated by copper homeostasis mechanisms. Proc. Am. Assoc. Cancer Res., 43: 423, 2002.
21. Samimi, G., Fink, D., Varki, N. M., Husain, A., Hoskins, W. J., Alberts, D. S., and Howell, S. B. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res., 6: 1415-1421, 2000.
22. La Fontaine, S. L., Firth, S. D., Camakaris, J., Englezou, A., Theophilos, M. B., Petris, M. J., Howie, M., Lockhart, P. J., Greenough, M., Brooks, H., Reddel, R. R., and Mercer, J. F. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J. Biol. Chem., 273: 31375-31380, 1998.
23. Terada, K., Schilsky, M. L., Miura, N., and Sugiyama, T. ATP7B (WND) protein. Int. J. Biochem. Cell Biol., 30: 1063-1067, 1998.
24. Pena, M. M., Lee, J., and Thiele, D. J. A delicate balance: homeostatic control of copper uptake and distribution. J. Nutr., 129: 1251-1260, 1999.
25. Naredi, P., Heath, D. P., Enns, R. E., and Howell, S. B. Cross-resistance between cisplatin, antimonite and arsenite in human tumor cells. J. Clin. Investig., 95: 1193-1198, 1994.
26. Ishida, S., Lee, J., Thiele, D. J., and Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctrl in yeast and mammals. Proc. Natl. Acad. Sci. USA, 99: 14298-14302, 2002.
27. Lin, X., Okuda, T., Holzer, A., and Howell, S. B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 62: 1154-1159, 2002.
28. Suzuki, M., and Gitlin, J. D. Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr. Int., 41: 436-442, 1999.
29. Moore, S. D., and Cox, D. W. Expression in mouse kidney of membrane copper transporters atp7a and atp7b. Nephron, 92: 629-634, 2002.
30. Chelly, J., Tumer, Z., Tonnensen, T., Petterson, A., Ishikawa-Brush, Y., Tommerup, N., Horn, N., and Monaco, A. P. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat. Genet., 3: 14-19, 1993.
31. Vulpe, C., Levinson, B., Whitney, S., Packman, S., and Gitshier, J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat. Genet., 3: 7-13, 1993.
32. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T-P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
33. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., and Howell, S. B. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res., 61: 1508-1516, 2001.
34. Lin, X., and Howell, S. B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol., 56: 390-395, 1999.